Boston Scientific buying cardiac health company Preventice Solutions in deal worth up to $1.2B
Boston Scientific Corp. said it has agreed to acquire Preventice Solutions Inc. for $925 million up front and up to an additional $300 million in a potential commercial milestone payment. The former has been an investor in Preventice since 2015 and currently holds an equity stake of about 22%, which is expected…
23andMe Raises More Than $80 Million in Equity Financing Round
DNA testing company 23andMe Inc. raised more than $80 million in equity in a financing round led by Sequoia Capital and NewView Capital. According to Securities and Exchanges Commission filings, the company offered $85 million in equity and sold about $82.5 million…
SomaLogic Adds $81M to Series A Financing Totaling $214M
SomaLogic, Inc., global leader in proteomic discovery and applications transforming biomedical discovery and clinical diagnostics, announced today that it added $81M to its current funding round with investments from a number of additional investors, for a total Series A raise of $214M.
Olympus Grows Respiratory Portfolio with Acquisition of Veran Medical Technologies, Inc.
Olympus Corporation today announced that it has entered into an agreement to acquire Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, for up to USD 340 million.
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 million, before underwriting discounts and commissions…
An Overview of GP-Led Restructurings
In this white paper, we cover:
Tender Offers: A Guide for Late-Stage Private Companies
In this white paper, we cover:
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participation from an unnamed strategic investor…
Acutus Medical Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today announced the closing of its initial public offering of 10,147,058 shares of common stock, which includes the exercise in full of the underwriters’ option….